Severe Asthma Management
Publication Date: October 1, 2019
Key Points
Key Points
Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.
Treatment
Treatment
...able 1. Recommendations for the Management...
...anti-IL-5 strategy as add-on therapy for adult pa...
...suggest that a blood eosinophil cut-point ≥150...
...ng a blood eosinophil cut-off ≥260 µL...
...using a FENO cut-off ≥19.5 ppb to id...
...dren, adolescents and adults with sever...
...st a trial of macrolide treatment to reduce asthm...
...inst the use of chronic macrolide treatment in c...
...suggest dupilumab as add-on therapy for adult...
...onoclonal Antibodies for Severe Asthma...